Risk assessment model for clotting problems in women with polycystic ovary syndrome
Studies hormone, metabolic and gene factors linked to clotting risk in women with PCOS.
Plain-language title generated from the registry record
Registry title: Construction of a Multi-dimensional Risk Assessment System: a Clinical Study of Polycystic Ovary Syndrome Complicated With Thrombophilia
Key facts
- Where
- Guangzhou, ChinaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for girls and women aged 14 to 45 years who have polycystic ovary syndrome (PCOS). It studies risk factors for blood clotting problems linked to low protein C and protein S.
- Age
- 14 to 45 years
- Sex
- Female only
- Disease stage
- Diagnosed polycystic ovary syndrome (PCOS), by adult or adolescent diagnostic rules, after other related disorders were ruled out.
- Earlier treatment
- No blood thinners, clotting-promoting drugs, birth control pills, or other drugs that may affect sex hormones, insulin, glucose metabolism or clotting in the 3 months before blood sampling.
Main reasons for not taking part
- Confirmed pregnancy
- Blood disease
- History of cancer
- Other disorders that can cause high male hormones or missed ovulation, such as thyroid disease or Cushing syndrome
- Disorders that can change protein C or protein S, such as antiphospholipid syndrome or liver disease
Read by machine on 12 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 14 and 45 years old?
Source: NCT07571096, who can take part
Where in China
- Guangdong Women and Children HospitalGuangzhou, ChinaContact: Li LiTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Guangdong Women and Children Hospital
- Trial code
- NCT07571096
- Record updated
- 30 July 2026
- Original description
This observational case-control study aims to develop a multidimensional risk assessment model for thrombophilia-related abnormalities in females with polycystic ovary syndrome (PCOS). The study will analyze endocrine, metabolic, and genetic factors associated with decreased protein C and/or protein S levels in participants with PCOS. The results are expected to provide evidence for risk stratification and individualized management in this population.Read full original descriptionShow less
Construction of a Multi-dimensional Risk Assessment System: a Clinical Study of Polycystic Ovary Syndrome Complicated With Thrombophilia
This observational case-control study aims to develop a multidimensional risk assessment model for thrombophilia-related abnormalities in females with polycystic ovary syndrome (PCOS). The study will analyze endocrine, metabolic, and genetic factors associated with decreased protein C and/or protein S levels in participants with PCOS. The results are expected to provide evidence for risk stratification and individualized management in this population.
Inclusion: Female participants aged 14 to 45 years; Diagnosis of polycystic ovary syndrome (PCOS); For adult participants, PCOS diagnosed according to the 2023 international evidence-based guideline. After exclusion of related disorders, diagnosis is based on ovulatory dysfunction and/or irregular menstrual cycles together with clinical hyperandrogenism, biochemical hyperandrogenism, or polycystic ovarian morphology on ultrasound where appropriate; For adolescent participants, PCOS diagnosed according to adolescent-specific recommendations. After exclusion of related disorders, both ovulatory dysfunction and/or irregular menstrual cycles and clinical or biochemical hyperandrogenism are required; Irregular menstrual cycles are defined as follows: more than 1 year and less than 3 years after menarche, menstrual cycles shorter than 21 days or longer than 45 days; more than 3 years after menarche to perimenopause, menstrual cycles shorter than 21 days or longer than 35 days, or fewer than 8 cycles per year; any cycle longer than 90 days more than 1 year after menarche; or primary amenorrhea by age 15 years or more than 3 years after thelarche; No use within 3 months before blood sampling of anticoagulant drugs, procoagulant drugs, oral contraceptives, or other medications that may affect sex hormones, insulin, glucose metabolism, or coagulation function.
Exclusion: Use of medications within 12 weeks before enrollment that may interfere with study assessments; Hematologic disease; History of malignant tumor; Disorders that may cause hyperandrogenism or ovulatory dysfunction, including congenital adrenal hyperplasia, Cushing syndrome, functional hypothalamic amenorrhea, thyroid disease, hyperprolactinemia, or primary ovarian insufficiency; Disorders that may affect protein C or protein S levels, including antiphospholipid syndrome, liver disease, or tumor-related conditions; Confirmed pregnancy; In adolescents, polycystic ovarian morphology alone will not be used to establish the diagnosis of PCOS.